期刊
ORPHANET JOURNAL OF RARE DISEASES
卷 8, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1750-1172-8-116
关键词
Fabry; Fibrosis; Podocyte; Lyso-Gb3; Kidney; Heart; Enzyme replacement therapy
资金
- Instituto de Salud Carlos III
- FEDER funds (ISCIIIRETIC REDINREN, FIS-Sara Borrel) [RD12/0021/0001, 0002, PS09/00447]
- Comunidad de Madrid (CIFRA) [S2010/BMD-2378]
- Genzyme foundation
- Programa Intensificacion Actividad Investigadora (ISCIII/Agencia Lain-Entralgo/CM)
- DZHI
Fabry disease is a rare X-linked hereditary disease caused by mutations in the AGAL gene encoding the lysosomal enzyme alpha-galactosidase A. Enzyme replacement therapy (ERT) is the current cornerstone of Fabry disease management. Involvement of kidney, heart and the central nervous system shortens life span, and fibrosis of these organs is a hallmark of the disease. Fibrosis was initially thought to result from tissue ischemia secondary to endothelial accumulation of glycosphingolipids in the microvasculature. However, despite ready clearance of endothelial deposits, ERT is less effective in patients who have already developed fibrosis. Several potential explanations of this clinical observation may impact on the future management of Fabry disease. Alternative molecular pathways linking glycosphingolipids and fibrosis may be operative; tissue injury may recruit secondary molecular mediators of fibrosis that are unresponsive to ERT, or fibrosis may represent irreversible tissue injury that limits the therapeutic response to ERT. We provide an overview of Fabry disease, with a focus on the assessment of fibrosis, the clinical consequences of fibrosis, and recent advances in understanding the cellular and molecular mechanisms of fibrosis that may suggest novel therapeutic approaches to Fabry disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据